The AHA contests PhRMA's conclusion in its new report that 340B program growth drives up drug costs for patients and employers.

PhRMA Slams 340B Hospitals in Report, AHA Returns Fire

The ability to generate profits through the 340B program prompts hospitals to buy physician practices and shift delivery of care to more costly hospital outpatient settings, driving up drug costs for patients and employers, Pharmaceutical Research and Manufacturers of America (PhRMA) says in a new report. The American Hospital Association (AHA) called the report “a misguided attack” on 340B.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content